Sharemaestro Newsreel

Biovica International AB (STU:9II) (Q1 2027) Earnings Call Highlights: Pharma Services Surge ...

This article first appeared on GuruFocus. Net Sales: SEK4 million, up 56% year over year (57% in local currency), driven primarily by pharma services. Operating Cash Flow: Minus SEK16 million, a modest improvement versus minus SEK17 million last year. Cash Position: SEK51.6 million, up …

Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA

MALMÖ, SE / ACCESS Newswire / September 10, 2026 / Ascelia Pharma (STO:ACE) completed the previously scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) on September 9, 2026, regarding the Complete Response Letter (CRL) for the Orviglance® New Drug Application …

Q1 Report - Focused Execution Driving Growth

Biovica delivered 56% sales growth in the first quarter, driven by strong Pharma Services momentum, while taking decisive actions to streamline operations, strengthen leadership, and position the company for its next phase of growth. UPPSALA, SE / ACCESS Newswire / September 9, 2026 / …

Notice of Extra General Meeting in Biovica International AB

UPPSALA, SE / ACCESS Newswire / September 9, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the extra general meeting to be held on Wednesday 30 September 2026, at 14:30 CEST …

AlzeCure Pharma to Present at Aktiedagen in Stockholm on September 15

STOCKHOLM, SE / ACCESS Newswire / September 8, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6) , which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that the company will participate in Aktiespararna's …

Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences

Egetis Therapeutics to Participate in Upcoming Investor Conferences in September

Vicore Pharma to Participate in Upcoming Healthcare Conferences

Number of shares and votes in BioArctic AB (publ) as of August 31, 2026

STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on …

Pila Pharma aktie • PILA

Chosa Oncology ökade förlusten i andra kvartalet

BioArctic AB (BRCTF) (Q2 2026) Earnings Call Highlights: FDA Approval of Leqembi Autoinjector ...

This article first appeared on GuruFocus. Global Leqembi Sales (Q2 2026): JPY29.3 billion (~$184 million), a 12% increase from Q1 2026 and a 27% increase from Q2 2025. Royalties (Q2 2026): Increased 12% to SEK179.4 million. Excluding a one-time stockpiling effect in Q2 2025, …

Corline Biomedical AB offentliggör delårsrapport för perioden januari till juni 2026

BioArctic: Interim Report for the period April - June 2026

New approvals for Leqembi® and additional strategic partnerships STOCKHOLM, Aug. 26, 2026 /PRNewswire/ -- Events during the second quarter 2026 Eisai provided a sales forecast for Leqembi for the company's fiscal year 2026 (April 2026 to March 2027) of a total of JPY 143.5 …

Vicore Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference

Noll i omsättning för Isofol Medical

Vicore Pharma to Present at the European Respiratory Society Congress 2026

Egetis Therapeutics AB (STU:P0F) (Q2 2026) Earnings Call Highlights: FDA Priority Review and US ...

Hansa Biopharma Files Confidential Draft for Potential US IPO

BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research

BioArctic and Mesenkia enter oncology research collaboration

STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeuticsannounced today that the companies have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain …

Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST

STOCKHOLM, August 19, 2026 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026, at 8:00 a.m. CEST. In conjunction with the report, BioArctic invites investors, analysts and …

AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction with Lilly

STOCKHOLM, SE / ACCESS Newswire / August 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company")(STO:ALZCUR)(FRA:AC6) , which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, announced today that it has now received the full upfront …

Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia

Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3 billion …

BioInvent Publication in JECCR: Tailored FcγR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models

Hansa Biopharma AB (FRA:24H) Q2 2026 Earnings Call Highlights: Transformative Growth and ...

BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026

Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

Camurus AB (CAMRF) Q2 2026 Earnings Call Highlights: Record Sales and Strategic Challenges

Biovica Appoints Maria Ekdahl as New Chief Financial Officer